Phase II Study Evaluating the Interest of Vismodegib as Neo-adjuvant Treatment of Basal Cell Carcinoma (BCC)
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 05 Jun 2018
Price : $35 *
At a glance
- Drugs Vismodegib (Primary)
- Indications Basal cell cancer
- Focus Therapeutic Use
- Acronyms VISMONEO
- 05 Jun 2018 Results (n=55) presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
- 11 Oct 2016 Results reporting characteristics of patients with locally advanced basal cell carcinoma and treated with neoadjuvant vismodegib and surgical resection, presented at the 41st European Society for Medical Oncology Congress.
- 26 Jan 2016 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov.